PDF(Sci-hub)
Abstract：
OBJECTIVE: To assess the safety and efficacy of CyberKnife® radiotherapy (CKRT) for the treatment of olfactory groove meningiomas (OGMs).
METHODS: A retrospective review was performed of 13 patients with OGM treated with CKRT from September 2005 to May 2018 at our institution. Nine patients were treated primarily with CKRT, 3 for residual disease following resection, and 1 for disease recurrence.
RESULTS: Five patients were treated with stereotactic radiosurgery (SRS), 6 with hypofractionated stereotactic radiotherapy (HSRT), and 2 with fractionated stereotactic radiotherapy (FSRT). The median tumor volume was 8.12 cm3. The median prescribed dose was 14.8 Gy for SRS, 27.3 Gy for HSRT, and 50.2 Gy for FSRT. The median maximal dose delivered was 32.27 Gy. Median post treatment follow-up was 48 months. Twelve of 13 patients yielded a 100% regional control rate with a median tumor volume reduction of 31.7%. Six of the 12 patients had reduced tumor volumes while the other 6 had no changes. The thirteenth patient had significant radiation-induced edema requiring surgical decompression. Twelve patients were alive and neurologically stable at the time of the review. One patient died from pneumonia unrelated to his CKRT treatment.
CONCLUSIONS: CKRT appears to be safe and effective for the treatment of OGMs.
METHODS: A retrospective review was performed of 13 patients with OGM treated with CKRT from September 2005 to May 2018 at our institution. Nine patients were treated primarily with CKRT, 3 for residual disease following resection, and 1 for disease recurrence.
RESULTS: Five patients were treated with stereotactic radiosurgery (SRS), 6 with hypofractionated stereotactic radiotherapy (HSRT), and 2 with fractionated stereotactic radiotherapy (FSRT). The median tumor volume was 8.12 cm3. The median prescribed dose was 14.8 Gy for SRS, 27.3 Gy for HSRT, and 50.2 Gy for FSRT. The median maximal dose delivered was 32.27 Gy. Median post treatment follow-up was 48 months. Twelve of 13 patients yielded a 100% regional control rate with a median tumor volume reduction of 31.7%. Six of the 12 patients had reduced tumor volumes while the other 6 had no changes. The thirteenth patient had significant radiation-induced edema requiring surgical decompression. Twelve patients were alive and neurologically stable at the time of the review. One patient died from pneumonia unrelated to his CKRT treatment.
CONCLUSIONS: CKRT appears to be safe and effective for the treatment of OGMs.
摘要：
目的：评估Cyberknife®放疗（CKRT）治疗嗅沟脑膜瘤（OGMs）的安全性和有效性。
方法：回顾性分析2005年9月至2018年5月在我院接受CKRT治疗的13例OGM患者。9例患者主要接受CKRT治疗，3用于切除后的残留病，1表示疾病复发。
结果：5例患者接受了立体定向放射外科（SRS）治疗，6采用大分割立体定向放射治疗（HSRT），和2分次立体定向放射治疗（FSRT）。中位肿瘤体积为8.12cm3。SRS的中位处方剂量为14.8Gy，HSRT为27.3Gy，FSRT为50.2Gy。递送的中值最大剂量为32.27Gy。治疗后中位随访时间为48个月。13例患者中有12例获得了100％的区域控制率，中位肿瘤体积减少了31.7％。12名患者中有6名肿瘤体积减少，而其他6名没有变化。第十三例患者有明显的放射性水肿，需要手术减压。在审查时，十二名患者还活着并且在神经系统上稳定。一名患者死于与CKRT治疗无关的肺炎。
结论：CKRT对于OGM的治疗似乎是安全有效的。
方法：回顾性分析2005年9月至2018年5月在我院接受CKRT治疗的13例OGM患者。9例患者主要接受CKRT治疗，3用于切除后的残留病，1表示疾病复发。
结果：5例患者接受了立体定向放射外科（SRS）治疗，6采用大分割立体定向放射治疗（HSRT），和2分次立体定向放射治疗（FSRT）。中位肿瘤体积为8.12cm3。SRS的中位处方剂量为14.8Gy，HSRT为27.3Gy，FSRT为50.2Gy。递送的中值最大剂量为32.27Gy。治疗后中位随访时间为48个月。13例患者中有12例获得了100％的区域控制率，中位肿瘤体积减少了31.7％。12名患者中有6名肿瘤体积减少，而其他6名没有变化。第十三例患者有明显的放射性水肿，需要手术减压。在审查时，十二名患者还活着并且在神经系统上稳定。一名患者死于与CKRT治疗无关的肺炎。
结论：CKRT对于OGM的治疗似乎是安全有效的。
